DelveInsight’s “Adrenocortical Carcinoma Market Insights, Epidemiology, and Market Forecast-2034” report offers an in-depth understanding of Adrenocortical Carcinoma, including historical and forecasted epidemiology, as well as Adrenocortical Carcinoma market trends in the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

To know in detail about the Adrenocortical Carcinoma market outlook, drug uptake, treatment scenario, and epidemiology trends, Click here @ Adrenocortical Carcinoma Market Outlook Report

Key Takeaways from Adrenocortical Carcinoma Market Report

• In March 2025, Dana-Farber Cancer Institute initiated a research study evaluating a combination of drugs as a potential treatment for rare genitourinary malignancies. The study includes four cohorts: bladder or upper tract carcinoma with variant histology, adrenocortical carcinoma, other rare genitourinary carcinomas, and any genitourinary carcinoma with neuroendocrine differentiation.
• In February 2025, Corcept Therapeutics initiated an extension study for relacorilant, a potent and selective glucocorticoid receptor (GR) antagonist. This study allows patients who have successfully completed a Corcept-sponsored parent study of relacorilant to continue therapy. Eligible patients must have completed their last treatment visit in the parent study and, in the investigator’s opinion, would benefit from continued treatment.
• In February 2025, Fusion Pharmaceuticals Inc. launched a first-in-human Phase 1/2 clinical study to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of [225Ac]-FPI-1434, a radioimmuno-therapeutic agent, in patients with solid tumors that demonstrate uptake of [111In]-FPI-1547, a radioimmuno-imaging agent. This non-randomized, multi-center, open-label study aims to establish the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) for repeat doses of [225Ac]-FPI-1434 injection.
• As per DelveInsight’s estimations, the total incident cases of ACC in the 7MM were approximately 12 hundred in 2023 and are projected to increase during the forecast period, owing to the Increasing incidence trends over decades and advancements in diagnostic tools contribute to a better understanding and identification of this rare malignancy.
• The total incident cases of ACC in the United States was approximately three hundred in 2023, and it is expected to increase at an estimated CAGR throughout the study period (2020-2034).
• Among the 7MM, EU4 and the UK accounted for nearly six hundred incident cases of ACC, and these cases are expected to increase during the forecast period (2023-2034).
• Among EU4 and the UK, Germany had the highest incident population of Adrenocortical Carcinoma, with ~160 cases in 2023. On the other hand, Spain had the lowest incident population in EU4 and the UK in 2023.
• In Japan, there were around two hundred incident cases of ACC in 2023. These cases are expected to increase at a significant CAGR.
• Stage-specific Incident Cases of ACC are segmented into four distinct stages. In the US, the distribution of ACC cases across stages reveals that Stage III has the highest cases at 38%, followed by Stage IV at 27%, Stage II at 20%, and Stage I at 15%.
• The gender-specific incident ACC cases within the 7MM indicated an approximate distribution of 40% in males and 60% in females.
• The highest proportion of ACC cases was estimated in the 41–60 years (53%) in EU4 and the UK, while the least cases were in the age group
• The leading Adrenocortical Carcinoma Companies such as Enterome/Bristol-Myers Squibb, UNICANCER, Fusion Pharmaceuticals, and others
• Promising Adrenocortical Carcinoma Therapies such as EO2401 + Nivolumab, Dostarlimab, [111In]-FPI-1547 Injection, and others

Get a Free sample for the Adrenocortical Carcinoma Market Forecast, Size & Share Analysis Report @ Adrenocortical Carcinoma Treatment Market Size

Adrenocortical Carcinoma Epidemiology Segmentation in the 7MM

• Adrenocortical Carcinoma Incident Cases

• Adrenocortical Carcinoma Stage-specific Incident Cases

• Adrenocortical Carcinoma Gender-specific Incident Cases

• Adrenocortical Carcinoma Age-specific Incident Cases

Download the report to understand which factors are driving Adrenocortical Carcinoma epidemiology trends @ Adrenocortical Carcinoma Prevalence

Adrenocortical Carcinoma Marketed Drugs

• LYSODREN (Mitotane): HRA Pharma/Bristol-Myers Squibb

The adrenal cytotoxic agent mitotane (LYSODREN) has a central role in the systemic treatment of Adrenocortical Carcinoma, a rare and aggressive cancer of the adrenal glands. Mitotane has been evaluated and used for more than 60 years and, to date, is the only drug specifically approved for the treatment of ACC. Although ACC continues to be associated with a poor prognosis, mitotane has been shown to provide clinically significant benefit in a good proportion of ACC patients treated with the drug, both in advanced disease and adjuvant therapy settings. Approved in 1970 in the US and 2004 in the European Union, LYSODREN is listed among the ‘Off-Patent, Off-Exclusivity Drugs without an Approved Generic’ as outlined in the Orange Book.

Adrenocortical Carcinoma Emerging Drugs

• EO2401 + Nivolumab: Enterome/Bristol-Myers Squibb

EO2401, a novel immunotherapy developed by Enterome from their proprietary OncoMimics platform, consists of three synthetic peptides mimicking human Tumor-Associated Antigens: IL13Ra2, BIRC5/Survivin, and FOXM1. These peptides, derived from bacteria, target aggressive cancers like glioblastoma and adrenal tumors with minimal impact on healthy tissues. Nivolumab, an immune checkpoint inhibitor, aids T cell expansion and infiltration into tumors.

To learn more about Adrenocortical Carcinoma treatment guidelines, visit @ Adrenocortical Carcinoma Clinical Trials Assessment

Adrenocortical Carcinoma Market Outlook

The Adrenocortical Carcinoma (ACC) market is poised for significant expansion, driven by advancements in treatment strategies and the introduction of novel therapies. The management of ACC primarily relies on adjuvant therapy, with Mitotane ± Streptozocin being the standard approach. However, the treatment paradigm is expected to evolve with the anticipated approval of promising pipeline therapies like EO2401 + Nivolumab, among others.

Adrenocortical Carcinoma Market Drivers

• The anticipated approval of promising drugs like EO2401 + Nivolumab and other innovative immunotherapies is set to revolutionize the ACC treatment landscape, providing more effective options for patients and boosting market growth.

• Rising investments in clinical trials, targeted therapies, and precision medicine approaches drive advancements in ACC treatment, enhance patient outcomes, and expand market opportunities.

Adrenocortical Carcinoma Market Barriers

• Despite ongoing research, ACC remains a rare and aggressive cancer with limited approved therapies, making disease management challenging and restricting market expansion.

• The expensive nature of novel therapies and challenges in reimbursement policies, particularly in developing and cost-sensitive markets, may hinder patient access and slow market penetration.

Learn more about the FDA-approved drugs for Adrenocortical Carcinoma @ Drugs for Adrenocortical Carcinoma Treatment

Scope of the Adrenocortical Carcinoma Market Report

• Study Period: 2020–2034

• Coverage: 7MM

• Adrenocortical Carcinoma Companies: HRA Pharma, Takeda Pharmaceuticals, Pfizer, Novartis, Bayer, Bristol-Myers Squibb, Ipsen Biopharmaceuticals, Exelixis, Genentech, Merck KGaA, and others.

• Adrenocortical Carcinoma Therapies: EO2401 + Nivolumab and others.

• Adrenocortical Carcinoma Therapeutic Assessment: Adrenocortical Carcinoma currently marketed, and Adrenocortical Carcinoma emerging therapies

• Adrenocortical Carcinoma Market Dynamics: Adrenocortical Carcinoma market drivers and Adrenocortical Carcinoma market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Adrenocortical Carcinoma Unmet Needs, KOL’s views, Analyst’s views, Adrenocortical Carcinoma Market Access and Reimbursement

Table of Contents

1. Adrenocortical Carcinoma Market Report Introduction

2. Executive Summary for Adrenocortical Carcinoma

3. SWOT analysis of Adrenocortical Carcinoma

4. Adrenocortical Carcinoma Patient Share (%) Overview at a Glance

5. Adrenocortical Carcinoma Market Overview at a Glance

6. Adrenocortical Carcinoma Disease Background and Overview

7. Adrenocortical Carcinoma Epidemiology and Patient Population

8. Country-Specific Patient Population of Adrenocortical Carcinoma

9. Adrenocortical Carcinoma Current Treatment and Medical Practices

10. Adrenocortical Carcinoma Unmet Needs

11. Adrenocortical Carcinoma Emerging Therapies

12. Adrenocortical Carcinoma Market Outlook

13. Country-Wise Adrenocortical Carcinoma Market Analysis (2020–2034)

14. Adrenocortical Carcinoma Market Access and Reimbursement of Therapies

15. Adrenocortical Carcinoma Market Drivers

16. Adrenocortical Carcinoma Market Barriers

17. Adrenocortical Carcinoma Appendix

18. Adrenocortical Carcinoma Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/functional-dyspepsia-pipeline-insight